NAAA and Thromboembolism: Platelet GPIIb/IIIa receptor blocker can inhibit the formation of thromboembolism by preventing fibrinogen binding to PLT IIb/IIIa receptors, which is the final pathway for PLT aggregation (Starnes et al., 2011).